Related to Protalix’ Phase III Candidate for Gaucher’s May Fill the Treatment Gap due to Genzyme’s Plant Closure

• FDA Approves Roche EGFR Mutation CDx for NSCLC
  
• Bayer Prostate Cancer Drug Gains FDA Approval
  
• FDA cGMP Complaints Draw Boehringer Ingelheim Promise of Action
  
• FDA Stalls Approval of Genzyme’s Pompe Disease Drug
  
• Shire Reports Positive Data from First Phase III Study of Gaucher’s Disease Therapy
  
• EMEA Issues Treatment Recommendations to Preserve Supply of Genzyme’s Gaucher’s Drug
  
• Shire’s Enzyme Replacement Therapy for Gaucher’s Continues to Succeed in Late-Stage Studies
  
• Genzyme to Give Up $175M in Profits under Consent Decree to Rectify Issues at Production Plant
  
• FDA Sanctions Alexion’s RI Production Plant for Commercial Supply of Soliris
  
• FDA Clears Expanded Access Program for Edison’s Mitochondrial Diseases Candidate
  
• Genzyme Gets FDA, EMA Approvals for Production Plant in Waterford, Ireland
  
• Exelixis Scores First FDA Approval for Thyroid Cancer Drug
  
• Pfizer, Protalix Beef Up Gaucher Disease Partnership
  
• Protalix’ Gaucher’s Therapy Demonstrated Positive Results in Phase III
  
• Pfizer Pays Protalix $60M for Global Rights to Plant-Produced Gaucher Therapy
  
• Shire Gains EC Nod for Gaucher Disease Treatment
  
• FDA Requests More Data from Existing Trials with Protalix’ Gaucher Disease Drug
  
• Shire’s Gaucher Disease Drug Candidate Being Considered by FDA
  
• Shire’s Gaucher Disease Therapy Gets FDA Green Light
  
• Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso